[Fibrosarcoma in children and adolescents: different entities for the same name]

Estelle Thebaud1, Aurélie Mezel, Xavier Leroy

  • 1CHU de Nantes, service d'oncologie et d'hématologie pédiatrique, Nantes, France.

Bulletin Du Cancer
|May 30, 2012
PubMed

Insights

Pediatric fibrosarcomas (FS) and mesoblastic nephroma (MN) share diagnostic challenges and histological similarities. Understanding their distinct clinical presentations and molecular underpinnings is crucial for effective multidisciplinary management.

Area of Science:

  • Pediatric Oncology
  • Molecular Pathology
  • Tumor Biology

Context:

  • Fibrosarcomas (FS) are rare pediatric non-rhabdomyosarcomas, with infantile and congenital subtypes presenting in young children.
  • Cellular or atypical mesoblastic nephroma (MN) is a pediatric renal tumor with histological overlap with congenital FS.
  • Adult-type FS can occur in older children, presenting with distinct aggressive behavior and metastasis.

Purpose:

  • To review the literature on pediatric fibrosarcomas and cellular mesoblastic nephroma.
  • To highlight diagnostic difficulties and histological similarities between these rare tumors.
  • To differentiate infantile FS, adult-type FS, and cellular MN based on clinical presentation, histology, and molecular findings.

Summary:

  • Infantile FS and adult-type FS share a name but differ in clinical presentation and outcome.
  • Congenital FS and cellular MN have different names and origins but similar histology, chromosomal rearrangements, and chemotherapy sensitivity.
  • Molecular detection of the ETV6-NTRK3 fusion protein aids in diagnosing FS.
  • Multidisciplinary management is essential for pediatric FS to avoid extensive surgery.

Impact:

  • Clarifies diagnostic criteria for rare pediatric mesenchymal tumors.
  • Improves understanding of the relationship between congenital FS and cellular MN.
  • Informs treatment strategies by differentiating tumor types and predicting outcomes.
  • Emphasizes the importance of molecular diagnostics in pediatric oncology.

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...